Probiotics for IBS: What the Evidence Actually Shows

Irritable bowel syndrome affects 10-15% of adults and is characterised by recurrent abdominal pain associated with altered bowel habits - diarrhoea, constipation, or both - in the absence of structural bowel disease. Dysbiosis - an imbalance in the composition and diversity of the gut microbiome - is consistently observed in IBS populations. IBS patients tend to have lower levels of Lactobacillus and Bifidobacterium species, altered Firmicutes-to-Bacteroidetes ratios, and higher intestinal permeability. Whether dysbiosis causes IBS symptoms or results from them remains debated, but the gut-microbiome connection is mechanistically and clinically established. Probiotics target this connection directly.

The evidence that probiotics reduce IBS symptoms is positive but strain-specific. A 2018 systematic review and meta-analysis in Alimentary Pharmacology & Therapeutics (Ford et al.) analysed 53 randomised controlled trials involving over 5,000 IBS patients and found that probiotics significantly reduced global IBS symptoms, abdominal pain, and bloating vs placebo. The relative risk for persistent symptoms was 0.79 (21% relative risk reduction). However, the authors noted significant heterogeneity between strains and formulations, and the effect is not uniform across all probiotic products. Strains with the strongest IBS evidence include: Bifidobacterium infantis 35624 (Whorwell et al., 2006 - landmark trial showing significant improvement in abdominal pain, bloating, and bowel habit), Lactobacillus plantarum 299v (Ducrotte et al., 2012 - abdominal pain and bloating), and multi-strain combinations including Bifidobacterium longum BB536.

IBS is classified into subtypes based on predominant bowel habit: IBS-D (diarrhoea predominant), IBS-C (constipation predominant), IBS-M (mixed), and IBS-U (unclassified). The evidence for probiotics is strongest for IBS-D, where reduced gut transit time and intestinal permeability are key mechanisms. Lactobacillus rhamnosus GG and Saccharomyces boulardii have the most evidence for diarrhoea-predominant IBS and antibiotic-associated diarrhoea. For IBS-C, Bifidobacterium strains that increase short-chain fatty acid production (particularly butyrate) and improve colonic motility are more relevant. Multi-strain probiotics covering both are practical for mixed or unclassified IBS.

Bloating is the most commonly reported and treatment-resistant IBS symptom. The mechanism involves excessive fermentation of undigested carbohydrates by colonic bacteria producing gas (hydrogen, methane, carbon dioxide). Probiotics may reduce bloating by: competitive exclusion of gas-producing dysbiotic bacteria, production of bacteriocins (antimicrobial compounds) that suppress competing fermenters, and modification of gut motility that reduces gas retention time. Several trials show meaningful bloating reduction with B. infantis and L. plantarum strains specifically. Symptom improvement typically requires 4-8 weeks of consistent use at appropriate CFU doses.

For IBS, strain identity is more important than total CFU count. The minimum effective doses used in IBS trials range from 10^8 to 10^10 CFU. Higher CFU products (50-100 billion CFU) are not necessarily more effective than evidence-dosed 10-25 billion CFU products if the strain composition is superior. The critical requirements: strains must be identified to species and strain level (not just "Lactobacillus acidophilus" but "L. acidophilus NCFM"), viability must be guaranteed to expiry date (not at manufacture), and the product must have third-party testing confirming identity and count. Enteric-coated or spore-based delivery systems improve gastric acid survival. Refrigerated storage generally better maintains viability than room-temperature products, though some lyophilized strains are shelf-stable.

LOOM Gut Health is formulated with strains that have documented evidence across IBS symptom categories - abdominal pain, bloating, and irregular bowel habit. The formulation specifies strains to the strain level, guarantees CFU viability to expiry, and is third-party tested for identity and potency. If you are managing IBS, consistent daily supplementation for a minimum of 8 weeks alongside dietary assessment is the evidence-aligned approach.